FundedIQ
Biotechnology

Ryvu

Ryvu is a biopharmaceutical company that is creating small-molecule treatments to overcome the challenges of current oncology therapies.

ryvu.com Krakow, Poland 251-500 employees
Total raised
$45.1M
Latest round: +24% of prior total
Rounds
3
Latest
Mar 2024

Ryvu is a biopharmaceutical company that is creating small-molecule treatments to overcome the challenges of current oncology therapies.

Ryvu has raised $45.1M across 3 rounds. Full funding history, investors, and team are detailed below.

Funding history

3 rounds · 1 visible Unlock with plan

3 rounds on record — latest round shown, the rest unlock with a paid plan.

Date
Round
Amount
Lead investor
Mar 6, 2024
$8.7M

Unlock 2 earlier rounds — dates, amounts, round types — plus the lead investor for every round.

Unlock funding history →

People

Unlock with plan

Founders, executives, and decision-makers — sourced and refreshed weekly.

Name
Role
LinkedIn

See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.

Unlock people data →

Ryvu is featured in

Similar companies

Proteine Resources

We're on a mission to revolutionize the use of insects, maximizing their potential in various industries. Our flagship product is a premium insect protein boasting 64% protein content in dry mass. What sets it apart are its remarkable medical properties, including unique amino and fatty acid profiles, as well as a rich array of vitamins and macro- and micronutrients. Even more impressive is its production efficiency — it can be produced 50% cheaper and at a larger scale, far outpacing any competition in the market. Our product range caters to the poultry feed, pet food, and veterinary supplement industries. These products are integral components of animal feeds, significantly reducing mortality rates, enhancing health, appearance, and overall well-being. Now, imagine the possibilities if we harness the bioactive compounds found in insects such as serotonin, melatonin, ecdysone, lovastatin, GABA, phenolic compounds, cordycepin, erinacenes, hericenones, psilocybin, psilocin, beta-glucan, and triterpenes. With these potent ingredients, we can develop high-value cosmetics and medicines tailored for specific therapeutic purposes, boasting exceptional bioavailability. This is the future of innovation in healthcare and beauty.

Venture - Series Unknown
Quantum Innovations

Quantum was created to develop solutions that address specific difficulties in cardiac surgery, cardiology, and respiratory medicine.

Series Unknown $10.2M
BioCam

BioCam designs and manufactures an endoscopic capsule for imaging of the digestive system along with AI-powered software for automatic detection and real-time determination of potential threats. The company's goal is to reduce the cost of gastrointestinal examinations, increase patient comfort, and popularization of capsule endoscopy.

Seed $480k
Orthoget

Orthoget is a progressive company specializing in bioengineering that has been engaged in research and innovation related to intramedullary implants for long bones.

Series Unknown $2.0M
immunitoAI

ImmunitoAI is a life sciences (biotech) platform that leverages AI to revolutionize antibody discovery & therapeutics.

Series A $6.1M
AI Metrics

AI Metrics is an early stage company creating transformational image analysis technology that positions radiologists to be the most efficient, valuable clinicians in the patient care continuum

Venture - Series Unknown $950k
Luminate Medical

Luminate Medical develops a medical device designed to prevent hair loss during chemotherapy. Luminate Medical recognises that hair is an essential element of personality and self-esteem, and is dedicated to using the latest advances in medical technology to protect this.

Venture - Series Unknown $17.0M
Hermes Biosciences

Hermes Biosciences describes a benchtop, hands-off extracellular vesicle isolation system designed to purify exosomes quickly, efficiently.

Seed $6.0M
InvenireX

InvenireX is a biotech company that provides molecular diagnostics services.

Seed $2.6M
Chromologics

Chromologics is a company that creates new and original food colorings utilizing natural ingredients. Derived from the Technical University of Denmark, this Danish biotech spin-out has established a biotech framework that employs fungi to generate exceptional and eco-friendly colorants.

Venture - Series Unknown $8.1M
Artios Pharma

Artios is an independent DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. Established in May 2016, the Company is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery. Artios is building a pipeline of next-generation DDR programs, including through a unique partnership with Cancer Research Technology (CRT), the development and commercialization arm of Cancer Research UK (CRUK), and with leading DNA repair researchers worldwide. The Company’s investors include SV Life Sciences, Merck Ventures, Imperial Innovations, Arix Bioscience PLC, CRT Pioneer Fund (managed by Sixth Element Capital), and AbbVie Ventures. Artios is based at the Babraham Institute in Cambridge, UK.

Series D $115M
Bambusa Therapeutics

Bambusa Therapeutics is a biotechnology company that specializes in the development of bispecific antibodies.

Series A
Free · Every Monday

Know which startups just got funded. Every week.

Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.

Free. Sent every Monday. Unsubscribe anytime.